Fidelity Investments
CLDI icon

Fidelity Investments’s Calidi Biotherapeutics CLDI Stock Holding History

Fidelity Investments’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61 Sell
255
-21,758
-99% -$16.3K ﹤0.01% 5284
2025
Q4 		$25.8K Buy
22,013
+21,888
+17,510% +$32.2K ﹤0.01% 4368
2025
Q3 		$190 Buy
+125
New +$531 ﹤0.01% 5158
2024
Q4 		– Sell
-12
Closed -$161 – 5596
2024
Q3 		$161 Buy
+12
New +$209 ﹤0.01% 5051

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments's CLDI Position: Q1 2026 in Review

Fidelity Investments reduced its Calidi Biotherapeutics (CLDI) stake by 99% in Q1 2026, selling an estimated $16.3K and leaving 255 shares worth $61. The position accounts for ﹤0.01% of the portfolio, ranked #5284.

Fidelity Investments first reported a position in CLDI in Q3 2024 and has held it in 4 quarters since. The position peaked at $25.8K in Q4 2025. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • Fidelity Investments held 255 shares of Calidi Biotherapeutics worth $61 as of Q1 2026.
  • Fidelity Investments sold 21,758 Calidi Biotherapeutics shares in Q1 2026, an estimated $16.3K.
  • Calidi Biotherapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5284 holding.
  • Fidelity Investments first reported a position in Calidi Biotherapeutics in Q3 2024 and has held it in 4 quarters since.
  • Fidelity Investments's Calidi Biotherapeutics position peaked at $25.8K in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.